Intellia Therapeutics (NASDAQ:NTLA) Upgraded at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research note released on Thursday, BidAskClub reports.

NTLA has been the subject of several other research reports. Zacks Investment Research lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Chardan Capital reissued a buy rating and set a $57.50 price objective on shares of Intellia Therapeutics in a research note on Tuesday, May 28th. Roth Capital began coverage on Intellia Therapeutics in a research note on Monday, June 10th. They set a neutral rating and a $16.00 price objective for the company. ValuEngine lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Monday, August 26th. Finally, Robert W. Baird began coverage on Intellia Therapeutics in a research note on Monday, July 8th. They set an outperform rating and a $23.00 price target for the company. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $25.56.

Shares of NASDAQ NTLA opened at $14.25 on Thursday. The stock has a market cap of $720.91 million, a PE ratio of -7.20 and a beta of 2.71. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99. The stock has a fifty day moving average of $16.18 and a 200-day moving average of $16.04.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. The company had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $7.15 million. Intellia Therapeutics had a negative return on equity of 33.03% and a negative net margin of 242.65%. The firm’s quarterly revenue was up 44.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.52) earnings per share. On average, sell-side analysts predict that Intellia Therapeutics will post -2.29 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its stake in Intellia Therapeutics by 277.9% during the second quarter. Royal Bank of Canada now owns 133,723 shares of the company’s stock worth $2,189,000 after purchasing an additional 98,339 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $539,000. Nuveen Asset Management LLC bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $2,416,000. UBS Asset Management Americas Inc. bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $299,000. Finally, Balyasny Asset Management LLC lifted its stake in shares of Intellia Therapeutics by 25.6% in the 2nd quarter. Balyasny Asset Management LLC now owns 57,321 shares of the company’s stock valued at $938,000 after acquiring an additional 11,675 shares during the last quarter. 79.39% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Recommended Story: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kinsale Capital Group Inc  Receives Consensus Rating of “Hold” from Brokerages
Kinsale Capital Group Inc Receives Consensus Rating of “Hold” from Brokerages
Bottos  Price Hits $0.0059 on Major Exchanges
Bottos Price Hits $0.0059 on Major Exchanges
Bitnation  Achieves Market Capitalization of $83,173.00
Bitnation Achieves Market Capitalization of $83,173.00
Snovian.Space Price Up 21.3% This Week
Snovian.Space Price Up 21.3% This Week
BitBall Achieves Market Capitalization of $145,668.00
BitBall Achieves Market Capitalization of $145,668.00
Analysts Set ProQR Therapeutics NV  Target Price at $25.67
Analysts Set ProQR Therapeutics NV Target Price at $25.67


 
© 2006-2019 Zolmax.